Short answer
TG THERAPEUTICS, INC. (TGTX) filed its fiscal 2025 10-K annual report with the SEC on Feb 27, 2026. It reported revenue of $616M (+87.3% year over year) and net income of $447M.
- Top risk flagged: Cybersecurity breach risk impacting drug candidate development and commercialization via failures in internal or third-party CROs, CMOs, or contractors
FY2025 key financial metrics · XBRL
- Revenue
- $616M
- +87.3% YoY
- Net income
- $447M
- +1812.4% YoY
- Operating margin
- 20.0%
- +7.3 pp YoY
- EPS (diluted)
- $2.77
- +1746.7% YoY
- ROE
- 69.0%
- +58.5 pp YoY
- Operating cash flow
- −$25M
- +38.9% YoY
Source: XBRL data from the TG THERAPEUTICS, INC. (TGTX) FY2025 10-K on SEC EDGAR. USD.
TG THERAPEUTICS, INC. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Fully integrated biotech focused on novel treatments for B-cell diseases, principally commercializing BRIUMVI for relapsing multiple sclerosis (RMS)
- New initiatives: Launched Next In MS™ awareness platform with Christina Applegate; initiated Phase 3 enrollment for subcutaneous ublituximab; dosed first patient with azer-cel CAR T therapy in Phase 1 for progressive MS
- Strategic shift: Expansion of BRIUMVI commercialization into Europe via $140M upfront deal with Neuraxpharm; emphasis on dosing schedule simplification and subcutaneous formulation development
- Notable metric: Completed $100M share repurchase, acquiring 3.5 million shares at $28.55 average; Phase 3 subcutaneous ublituximab trial over 75% enrolled as of Feb 2026
- Unique fact: Presented six-year data from ULTIMATE I & II trials showing 89.9% patients free from confirmed disability progression and ARR of 0.012, indicating sustained long-term efficacy and safety
Management Discussion & Analysis
- No capital allocation details such as buybacks, dividends, or capex mentioned
- Forward-looking statements include general caution on risks and uncertainties
Risk Factors
- Cybersecurity breach risk impacting drug candidate development and commercialization via failures in internal or third-party CROs, CMOs, or contractors
- Management oversight of cybersecurity risks with Board receiving regular reports on material threats and IT security effectiveness
- Vice President of IT responsible for cybersecurity risk management, holds multiple certifications, with 25+ years experience
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.